Linagliptin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Linagliptin
Linagliptin.png
Systematic (IUPAC) name
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Clinical data
Trade names Tradjenta, Trajenta
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611036
License data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
Legal status
Legal status
Pharmacokinetic data
Bioavailability 30% oral
Protein binding 75% to 99% in plasma
Identifiers
CAS Number 668270-12-0 YesY
ATC code A10BH05 (WHO)
PubChem CID 10096344
IUPHAR/BPS 6318
ChemSpider 8271879 N
UNII 3X29ZEJ4R2 YesY
KEGG D09566 YesY
ChEMBL CHEMBL237500 N
Chemical data
Formula C25H28N8O2
Molar mass 472.54 g/mol
 NYesY (what is this?)  (verify)

Linagliptin (BI-1356, trade names Tradjenta (US), Trajenta (worldwide)) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.

Linagliptin (once-daily) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes.[1] It is being marketed by Boehringer Ingelheim and Lilly.

Medical uses[edit]

Results in 2010 from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.[2]

Side effects[edit]

They may cause severe joint pain.[3]

Mechanism of action[edit]

See also[edit]

References[edit]

  • H. Spreitzer (September 1, 2008). "Neue Wirkstoffe - BI-1356". Österreichische Apothekerzeitung (in German) (18/2008): 918. 
  • Wang, Y, Serradell, N, Rosa, E, Castaner, R (2008). "BI-1356". Drugs of the Future 33 (6): 473–477. doi:10.1358/dof.2008.033.06.1215244. 

External links[edit]